Protocol Title:

A single arm, multicenter, prospective, open label, longitudinal Phase 3 study of prostate specific membrane antigen (PSMA) positron emission tomography (PET) combined with magnetic resonance imaging (MRI) compared to standard of care (SOC) for the detection of prostate cancer (PCa).

Protocol Number: ^{68}Ga-TLX007-CDx-301

Version Number & Date: Version 3.0, 11-Aug-2025

Compound: ^{68}Ga-PSMA-11

Brief Title: PSMA PET combined with MRI for the detection of PCa

Study Phase: Phase 3

Sponsor Name: Telix Innovations S.A.

Sponsor Address: Rue de Hermée, 255 4040 Herstal, Belgium

Confidentiality Statement

Duration:

Individual participation will be up to 7 months (+/- 14 days) including up to 31 days of screening and up to 6 months of follow-up.

Number of Participants: 204

The study population will be comprised of approximately 204 participants who have passed screening assessments, complied with eligibility criteria and have provided written consent.

Inclusion Criteria:

Participants are eligible to be included in the study only if all the following criteria apply:

1. Male, at least 18 years old.
2. Have a clinical suspicion of PCa, and indicated for template biopsy after having received an MRI demonstrating PI-RADs 1-4 within 3 months of enrollment and/or have non-imaging risk factors (including but not exclusive to):
    a) Persistently elevated or rising PSA
    b) High PSA density
    c) Abnormal digital rectal examination (DRE)
    d) Strong family history of prostate cancer:
        i. First-degree relative (father or brother) with PCa

ii. Any relative diagnosed at <65 years of age
iii. Multiple affected relatives
iv. Known hereditary cancer syndromes (e.g BReast CAncer gene [BRCA]1/2, Homeobox protein Hox-B13 [HOXB13] mutations)

e) Other high-risk biomarkers
i. 4Kscore
ii. PHI (Prostate Health Index)
iii. High Prostate Cancer Antigen 3 (PCA3)
iv. Any other established biomarker with values in the high-risk range

f) Clinical presentation
i. Symptoms suggestive of locally advanced disease (e.g urinary obstruction, bone pain)
ii. Prior negative MRI with ongoing clinical concern

3. Prostate biopsy naïve.
4. Eastern Cooperative Oncology Group performance status (ECOG PS) ≤2 per FDA guidelines
5. Have the capacity to understand the study and be able and willing to comply with all protocol requirements.
6. Provides consent for anatomical template with/without targeted biopsy based on clinical risk, MRI and PSMA PET result.
7. Participants must comply with the radiation protection rules (including hospital admissions and isolation) that are used by the treating institution to protect their contacts and the general public, especially if a female partner of the participant is or could be pregnant.
8. Must agree to practice adequate precautions to prevent pregnancy in a female partner and to avoid potential problems associated with radiation exposure to the unborn child (Recommendations related to contraception and pregnancy testing in clinical trials Version 1.1, Clinical Trial Facilitation Group, 2020). Details of contraceptive measures to be taken by male participants and their female partners are described in Appendix 4.

Exclusion Criteria:

A participant will be excluded from the study if he meets any of the following:

1. Has prior diagnosis of csPCa.
2. Previous diagnosis of cancer of any primary origin (excluding basal cell carcinoma or squamous cell carcinoma of the skin that has undergone potentially curative therapy).
3. Active prostate infection, or urinary test results suggestive of an active urinary tract infection, evident on medical history, within 4 weeks of enrollment.
4. Prior pelvic irradiation
5. Demonstrate radiographic findings of PI-RADS 5.

6. Has abnormalities in physical examination and protocol-specified clinical laboratory tests during the Screening Period that, in the judgment of the investigator, could affect safety or compliance; and/or is deemed not suitable for participating in this trial in the opinion of the investigator.
7. Unable to understand or is unwilling to sign a written informed consent document or to follow investigational procedures in the opinion of the investigator.
8. Is unable to attain or remain in a supine position while a PET/CT scan is being performed or unable to tolerate a PET/CT scan.
9. Unable or unwilling to undergo clinical prostate biopsy,
10. Has known allergies, hypersensitivity, or intolerance to the investigational drug/comparator or its excipients.
11. Have prior use of radionuclides within an interval of less than 10 effective half-lives before the administration of 68Ga-PSMA-11.
12. Is participating or plans to participate in any experimental drug or device trial during the study period that are considered outside of therapeutic SOC. Studies involving modifications of sequencing or timing of therapeutic regimens/interventions would be deemed eligible to enroll.